Understanding why some patients with Merkel cell carcinoma resist immunotherapy
Identifying the Mechanism of Resistance to Immunotherapy in Merkel Cell Carcinoma (for Zachary Reinstein)
This study is looking into why some people with Merkel cell carcinoma, a tough type of skin cancer, don’t respond well to immunotherapy, and it hopes to find clues that could help improve treatment for those patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11031967 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the resistance to immunotherapy in patients with Merkel cell carcinoma (MCC), a highly aggressive skin cancer. By analyzing a large database of MCC samples treated with immune checkpoint blockade, the study aims to identify specific T cells that contribute to treatment responses. The researchers will explore the interactions between these T cells and tumor cells to uncover the mechanisms of resistance and potential biomarkers for predicting treatment outcomes. This work could lead to improved strategies for treating patients who do not respond to current immunotherapy options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Merkel cell carcinoma, particularly those who have undergone immunotherapy.
Not a fit: Patients with other types of cancer or those who have not been diagnosed with Merkel cell carcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients with Merkel cell carcinoma who currently do not benefit from immunotherapy.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in other cancers, suggesting that this approach may yield valuable insights for Merkel cell carcinoma as well.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Reinstein, Zachary Zale — Northwestern University at Chicago
- Study coordinator: Reinstein, Zachary Zale
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.